GlaxoSmithKline

February 5, 2012

2012 Preview: Cancer Immunotherapy Catalysts

December 14, 2011 By MD Becker Partners 1 Comment

MD Becker Partners' Life Science Digest: 2012 graphic

2012 represents a period with robust news flow for emerging immuno-oncology companies

Filed Under: Articles Tagged With: AE37, AGEN, Agenus, Allovectin, Amgen, AMGN, Antigen Express, BAVA, Bavarian Nordic, BMY, Bristol-Myers Squibb, cancer vaccine, castrate-resistant prostate cancer, CELG, Celgene, Celldex Therapeutics, CLDX, cv-301, Dendreon, DNDN, Generex, GlaxoSmithKline, GlobeImmune, GNBT, gp100, GSK, HyperAcute, Idera Pharmaceuticals, IDRA, immunotherapy, IMO-2055, ipilimumab, Jennerex, JX-594, MAGE-A3, melanoma, NewLink Genetics, NLNK, NSCLC, Oncothyreon, OncoVex, ONTY, pancreatic cancer, panvac, PROSTVAC, Provenge, QS-21, sipuleucel-T, Stimuvax, TG4010, transgene, Vical, VICL, Yervoy

Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution

September 18, 2011 By MD Becker Partners Leave a Comment

MD Becker Partners' Life Science Digest: Adjuvants

Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.

Filed Under: Articles Tagged With: 3M Company, adjuvant, AE37, AGEN, Agenus, aluminum salts, Antigen Express, antigen-specific cancer immunotherapeutic, AS15, BARDA, Biomedical Advanced Research and Development Authority, BMY, Bristol-Myers Squibb, cancer immunotherapy, Cationic Lipid-DNA Complex, CDX-1401, Celldex Therapeutics, Cervarix, CLDX, Colby Pharmaceutical Company, Corixa Corporation, CpG, CyMVectin, Dendreon Corporation, DNDN, Generex Biotechnology, GLA, GlaxoSmithKline, glucopyranosyl lipid A, GNBT, GSK, Idera Pharmaceuticals, IDRA, Ii-Key hybrid technology, Immune Design Corporation, IMO-2055, ipilimumab, Juvaris BioTherapeutics, JVRS-100, MAGE-A3, MF59, MMM, monophosphoryl lipid A, Mosquirix, MPL, pandemic influenza, Provenge, QS-21, Quillaja saponaria, resiquimod, saponin, sipuleucel-T, squalene, TLR, toll-like receptor, Vaxfectin, Vical Inc., VICL, Yervoy

Cancer Immunotherapy: A Roundtable Discussion

June 30, 2011 By MD Becker Partners 3 Comments

meeting desk

Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.

Filed Under: Articles Tagged With: AGS-003, Allovectin-7, American Society of Clinical Oncology, Amgen, AMGN, AnGes, Argos Therapeutics, ASCO, AVAX Technologies, Bavarian Nordic, belagenpumatucel-L, BiovaxID, Biovest International, BLP25 liposome vaccine, BVTI, cancer immunotherapy, Cancer Research Institute, CDX-110, Celldex Therapeutics, CRI, GBM, GlaxoSmithKline, glioblastoma, GSK, Lucanix, MAGE-AS ASCI, melanoma, Merck KGA, MVA-MUC1-IL2, Novartis, Novarx, NSCLC, Oncothyreon, OncoVEX(GM-CSF), prostate cancer, PROSTVAC, rindopepimut, Stimuvax, TG4010, transgene, Vical, VICL

Drug Development Spotlight: The mTOR’s New Clothes?

November 22, 2010 By MD Becker Partners Leave a Comment

MD Becker Partners' Life Science Digest: Drug Development Spotlight - The mTOR’s New Clothes?

In 1837, Hans Christian Andersen authored a short tale titled The Emperor’s New Clothes. The main character, so enamored by his appearance and his clothing that he had a different suit for every hour of the day, was swindled by a pair of weavers purporting that they could create clothing from a magical fabric that [...]

Filed Under: Articles Tagged With: AEterna Zentaris, AEZS, Afinitor, Akt, American Society of Clinical Oncology, American Society of Hematology, ARIA, ARIAD Pharmaceuticals, ASCO, ASH, Astellas Pharma, AstraZeneca plc, AZD8055, AZN, BAY80-6946, Bayer, BAYRY.PK, BEZ235, BGT226, BKM120, BYL719, CAL-101, Calistoga Pharmaceuticals, Emperor's New Clothes, everolimus, EXEL, Exelixis, GDC-0980, GDC0941, GlaxoSmithKline, GSK, GSK2126458, Hans Christian Andersen, INK128, Intellikine, Keryx Biopharmaceuticals, KRAS, MAPK, Merck, MK2206, MRK, mTOR, mTORC1, mTORC2, Novartis AG, NVS, Oncothyreon, ONTY, OSI-027, Perifosine, PF-04691502, PFE, Pfizer, PGNX, phosphatidylinositol 3-kinase, pi3k, PIK3CA, PKI-587, prodrug, Progenics Pharmaceuticals, PX-866, rapamycin, RHHBY.PK, Ridaforolimus, Roche Holding AG, Sanofi-Aventis, Semafore Pharmaceuticals, SF1126, SNY, Temsirolimus, Torisel, Triciribine, VioQuest Pharmaceuticals, VOQP.PK, XL147, XL765

Cancer Vaccine Therapies: Failures and Future Opportunities

April 7, 2010 By MD Becker Partners 3 Comments

FIGURE 1: FDA APPROVAL OF CANCER MABS FROM 1997-2010

(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy. Cancer immunotherapy broadly includes passive immunization, active immunization, [...]

Filed Under: Articles Tagged With: active immunotherapy, AGEN, allogeneic, Allovectin-7, American Society for Clinical Oncology, Antigenics, Arzerra, ASCO, autologous, Bavarian Nordic, BIIB, Biogen Idec, Biologics License Application, biotechnology, BiovaxID, Biovest International, BMY, Bristol-Myers Squibb Company, BVTI, cancer vaccine, CD20, CDX-110, Celldex Therapeutics, CTLA-4, Dendreon, dendritic cells, DNDN, EGFRvIII, Genmab A/S, GlaxoSmithKline, GM-CSF, gp100, GSK, GVAX, immunotherapy, ipilimumab, life sciences, lung cancer, MAGE-3, MAGE-A3 ASCI, MD Becker Partners, melanoma, monoclonal antibodies, NCI, NHL, non-Hodgkin’s Lymphoma, NSCLC, ofatumumab, Oncophage, passive immunotherapy, PDUFA, PFE, Pfizer, prostate cancer, prostatic acid phosphatase, PROSTVAC, Provenge, RHHBY, Rituxan, rituximab, Roche Group, sipuleucel-T, TRICOM, vaccine, Vical, VICL